Background: Targeting autophagy at gene level may be promising in multiple myeloma (MM) treatment depending on chromosomal abnormality (ABN) status. Objectives: We aimed to investigate the role of ABN on survival of MM patients and to identify prognosis related autophagy-related genes (ARGs) for patients with or without ABN. Methods: Gene intensity values of 222 ARG for 548 MM patients were obtained from the Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) platform containing 54,675 probes (GSE24080). A dataset containing data from 1576 MM patients with 1q21 amplification (GSE4204, GSE4452, GSE4581, and GSE2658) was used for validation. Survival analysis of the patients was analyzed using univariate and multivariate Cox regression method with the help of R3.53 programming language and Kaplan–Meier graphics were created. The Gene Ontology enRIchmentanaLysis and visuaLizAtion (GOrilla) tool was used to define the related biological processes and pathways. Results: The overall survival (OS) and event-free survival (EFS) in all MM patients were strongly influenced by ABN. In the group of patients with ABN, 41 ARGs were found to be important in prognosis, whereas in the group of patients without ABN, 13 ARGs were found to be important in prognosis. CDKN1A , FKBP1B , FOXO3 , and NCKAP1 ARGs were commonly significant in both groups and found to be survival triggering. Conclusions: The classification of MM patients according to the absence or presence of ABN is important in the determination of survival status. Detection of survival related ARGs in patients with chromosomal anomalies may be a new therapeutic target in treatment.
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.
2 January 2025 in European Journal of Breast Health
Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs - European Journal of Breast Health
6 March 2024 in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
Kolanjiyokarsinom (CHOL) erken teşhis edilmesi zor olan ve oldukça yüksek düzeyde öldürücü bir kanser türüdür. CHOL tanısında radyolojik görüntülemede kısıtlılıklar mevcuttur ve biyopsi ile tanı yöntemi gibi invaziv tanı yöntemleri dışında genetik tabanlı ve özgün biyobelirteçlerin belirlenmesi zorunlu hale gelmektedir. Literatürde bu amaçlar gerçekleştirilen çalışmalar çalışmalardan farklı olarak bizim çalışmamızda öncelikle intrahepatik (iCHOL) ve ekstrahepatik (eCHOL) kolanjiyokarsinom hastalarında ortak upregüle olan genler belirlenmiştir. Ayrıca çalışmamızda klinikte CHOL kanserlerinin LIHC kanserinden ayırt edici tanısının zor olması sebebiyle CHOL hastalarında hepatoselüler karsinomdan (LICH) farklı olarak ve LIHC hastaları ile ortak olarak upregüle edilen genlerin tespit edilmesi de amaçlanmıştır. Hastaların gen yoğunluk verileri NCBI Gene Expression Omnibus (GEO) veri tabanından (GSE121248, GSE132305 ve GSE45001) sağlanmıştır. Çalışmada R LIMMA paketinde yer alan lineer modelleme yöntemi kullanılarak kanserli olan ve olmayan örnekler arasında upregüle genler (differentially expressed genes-DEGs) tespit edilmiştir. Tespit edilen genlerin hangi biyolojik yolaklara etki ettiğini belirlemek için Gen seti zenginleştirme analizi (Fonksiyonel zenginleştirme analizi) (GSEA) ShinyGO 0.80 webtool kullanılarak yapılmıştır. Sonuçlarımıza göre CHOL hastalarında LIHC hastalarından farklı olarak upregüle edilen 4 gene (F2R, ITGA11, LAMC2 ve LAMB3) odaklanılmıştır. CHOL ve LIHC hastalarında ise ortak olarak upregüle edilen 2 gen (COL1A1, ITGA2) tespit edilmiştir. Söz konusu genlerinin ortak olarak işaret ettiği biyolojik yolaklar PI3K-Akt sinyal yolağı ve ekstraselüler matriks (ECM)-reseptör etkileşimi süreçleridir. Belirlenen genler ile protein-protein ve ilaç etkileşim çalışmaları sonuçları klinik denemeler ile desteklenip CHOL ile LIHC kanserlerinin ayırt edilmesinde etkin bir şekilde hedeflenebilecektir.
20 November 2023 in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
Background: Pan-cancer research has recently been conducted to identify genomic differences in multiple cancers compared with those in normal tissues. Our aims were to determine common differentially expressed genes (DEGs) by analysing the genomes of multiple cancers and to identify common cancer biomarkers for both diagnosis and treatment by determining the effect of these commonly changed genes on survival. Methods: We performed DEG and survival analyses by considering differences in expression levels in tumour and related normal tissues using the R programme and bioinformatic webtools Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, TIMER2.0, KM-plot, ShinyGO 0.77, miRTargetLink, and CancerMIRNome. Results: In our study, 5 genes (ribonucleotide reductase regulatory subunit M2 (RRM2), enhancer of the zeste homolog 2 (EZH2), Proliferating cell nuclear antigen (PCNA) clamp associated factor (PCLAF), mitotic checkpoint serine/threonine kinase B (BUB1B), and centromere protein U (CENP-U)) were found to be upregulated in multiple cancers. Among these genes, the RRM2 gene was upregulated in more cancers and datasets. According to the gene enrichment analysis, the EZH2 gene also acted together with the RRM2 gene in terms of biological significance. Furthermore, instead of finding chemical agents that would inhibit the overexpression of both the RRM2 and EZH2 genes, miRNA screening targeting both genes were performed. As a result, hsa-let-7a-5p miRNA was found to have a strong interaction with both genes through the p53- and cell cycle-dependent pathways. Conclusion: The commonly upregulated RRM2 and EZH2 genes can be utilised as biomarkers for early diagnosis of multiple cancers. The joint interactions of the RRM2 and EZH2 genes with hsa-let-7a-5p may be a promising early treatment by inhibiting the expression levels of both genes by targeting hsa-let-7a-5p, an miRNA with low expression levels in cancers.